With 0.96 million shares changed hands, the volume of the stock remained lighter than its average volume of 10.44 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.64 whereas the lowest price it dropped to was $1.37. The 52-week range on NBY shows that it touched its highest point at $2.93 and its lowest point at $0.30 during that stretch. It currently has a 1-year price target of $0.85. NBY paid its most recent dividend on 1759190400, while the ex-dividend date for that was 1759190400. Beta for the stock currently stands at 0.57.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NBY was up-trending over the past week, with a rise of 8.16%, but this was down by -13.63% over a month. Three-month performance surged to 267.98% while six-month performance rose 304.65%. The stock gained 285.13% in the past year, while it has gained 235.89% so far this year.
Float and Shares Shorts:
At present, 5.82 million NBY shares are outstanding with a float of 4.77 million shares on hand for trading. On 2025-09-15, short shares totaled 0.85 million, which was 1461.0000000000002 higher than short shares on 1755216000. In addition to Mr. Tommy Law as the firm’s Controller, Interim CFO & Treasurer, Mr. Justin M. Hall Esq., J.D. serves as its VP of Business Dev., General Counsel, Chief Compliance Officer, Corporate Secretary & Director.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, NBY reported revenue of $0.0 and operating income of $-1891000.0. The EBITDA in the recently reported quarter was $-1926000.0 and diluted EPS was $-0.33.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NBY since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $-3.26 being high and $-3.26 being low. For NBY, this leads to a yearly average estimate of $-3.26. The surprise factor in the prior quarter was $-0.31.
